KRAS and pancreatic neoplasm: Recently, a new phosphodiesterase-δ (PDEδ) inhibitor, Deltazinone 1, binds to the prenyl-binding pocket of PDEδ, interferes with proper K-RAS-PDEδ interaction, impairs the proper plasma membrane attachment of prenylated K-RAS, and impedes proper K-RAS signaling in pancreatic cancer cells in vitro and in vivo [98,99,100].